alexa Patients with schizophrenia previously stabilized on conventional depot antipsychotics experience significant clinical improvements following treatment with long-acting risperidone.


Journal of Psychiatry

Author(s): Lasser RA, Bossie CA, Gharabawi GM, Turner M

Abstract Share this page

Abstract BACKGROUND: Conventional depot antipsychotics can provide constant pharmacologic treatment, eliminating partial compliance and reducing relapse risk. Atypical antipsychotics, have improved clinical profiles but require daily dosing, compromising their overall effectiveness. As oral risperidone provides safety and efficacy benefits over oral haloperidol, improvements may be realized by replacing conventional with atypical agents in long-acting therapy. This report examines 50-weeks of long-acting risperidone therapy in patients previously stabilized with conventional depot antipsychotics. METHODS: A multi-center, open-label study enrolled 725 patients with schizophrenia or schizoaffective disorder, judged clinically stable and maintained on stable antipsychotic doses for > or =4 weeks. Assignment by clinician judgment to receive 25-75 mg of long-acting risperidone every 2 weeks for 50 weeks followed, with performance of standard safety and efficacy assessments. Data are presented on patients receiving conventional depot antipsychotic monotherapy at study entry. RESULTS: In the 188 (25.9\%) patients receiving conventional depot antipsychotic monotherapy at entry, mild-to-moderate mean (+/-S.D.) Positive and Negative Syndrome Scale (PANSS)-total scores improved significantly after receiving long-acting risperidone (64.2 +/- 18.9 to 58.2 +/- 20.3; P < 0.001). Clinical improvement of > or =20\%, 40\%, or 60\% reduction in PANSS-total score, occurred in 52\%, 34\%, and 16\% of patients, respectively. ESRS subjective ratings and objective physician ratings (Parkinsonism) decreased significantly (P < 0.001). CONCLUSION: Stable patients with mild, residual symptomatology treated with conventional depot antipsychotics experienced significant improvement in psychiatric and movement disorder symptomatology following 1-year of treatment with long-acting risperidone. This article was published in Eur Psychiatry and referenced in Journal of Psychiatry

Relevant Expert PPTs

Relevant Speaker PPTs

  • Renata Karina Reis
    Prevalence of and factors associated with depressive symptoms in individuals living with HIV/AIDS in Brazil
    PPT Version | PDF Version
  • JoaoLuis Alves Apostolo
    The effectiveness of a cognitive stimulation therapy on elders cognition and depressive symptoms
    PPT Version | PDF Version
  • Ray Marks
    Depressive symptoms among older adults with mild to moderate Knee osteoarthritis are highly prevalent and are predicted by disease management self-efficacy: A cross-sectional study of depressive symptom prevalence, and clinical interrelationships
    PPT Version | PDF Version

Recommended Conferences

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version